1. Home
  2. AKBA vs NRK Comparison

AKBA vs NRK Comparison

Compare AKBA & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • NRK
  • Stock Information
  • Founded
  • AKBA 2007
  • NRK 2002
  • Country
  • AKBA United States
  • NRK United States
  • Employees
  • AKBA N/A
  • NRK N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • NRK Trusts Except Educational Religious and Charitable
  • Sector
  • AKBA Health Care
  • NRK Finance
  • Exchange
  • AKBA Nasdaq
  • NRK Nasdaq
  • Market Cap
  • AKBA 861.7M
  • NRK 824.4M
  • IPO Year
  • AKBA 2014
  • NRK N/A
  • Fundamental
  • Price
  • AKBA $2.88
  • NRK $10.14
  • Analyst Decision
  • AKBA Strong Buy
  • NRK
  • Analyst Count
  • AKBA 5
  • NRK 0
  • Target Price
  • AKBA $6.90
  • NRK N/A
  • AVG Volume (30 Days)
  • AKBA 2.9M
  • NRK 187.3K
  • Earning Date
  • AKBA 11-06-2025
  • NRK 01-01-0001
  • Dividend Yield
  • AKBA N/A
  • NRK 4.10%
  • EPS Growth
  • AKBA N/A
  • NRK N/A
  • EPS
  • AKBA N/A
  • NRK N/A
  • Revenue
  • AKBA $203,733,000.00
  • NRK N/A
  • Revenue This Year
  • AKBA $43.91
  • NRK N/A
  • Revenue Next Year
  • AKBA $32.09
  • NRK N/A
  • P/E Ratio
  • AKBA N/A
  • NRK N/A
  • Revenue Growth
  • AKBA 16.75
  • NRK N/A
  • 52 Week Low
  • AKBA $1.26
  • NRK $8.95
  • 52 Week High
  • AKBA $4.08
  • NRK $11.09
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 47.89
  • NRK 65.20
  • Support Level
  • AKBA $2.83
  • NRK $10.12
  • Resistance Level
  • AKBA $3.02
  • NRK $10.18
  • Average True Range (ATR)
  • AKBA 0.12
  • NRK 0.07
  • MACD
  • AKBA 0.03
  • NRK -0.01
  • Stochastic Oscillator
  • AKBA 56.94
  • NRK 48.31

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About NRK Nuveen New York AMT-Free Quality Municipal Income Fund

Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: